
News

-
FDA Warns of Heart Problems and Cancer with Arthritis Drug Xeljanz
The arthritis and ulcerative colitis drug Xeljanz (tofacitinib) could potentially increase the risk of heart-related problems and cancer, according to a February 2021… -
Analysis: Zantac May Form High Levels of Toxic NDMA in the Body
An analysis published in the Journal of the American Medical Association (JAMA) Network Open, suggests Zantac and drugs containing ranitidine may cause high… -
Adverse Drug Events: What Consumers Need to Know
In 2019, pharmacies filled an estimated 4.38 billion prescriptions. When you pick up your medication, it comes with a paper or booklet containing… -
AFFF Firefighting Foam Lawsuits Filed Over Cancer Risk
A growing number of firefighters have filed lawsuits that claim toxic chemicals in AFFF firefighting foam caused them to develop cancer, according to… -
Eisai Loses Motion to Dismiss Design Defect Claim in Belviq Cancer Lawsuit
Eisai Inc. and Arena Pharmaceuticals Inc. failed to get design defect claims dismissed in a lawsuit that alleges the weight loss drug Belviq… -
Cancer & COVID-19 Risk: A Q&A with Dr. Gary Lyman
Anyone exposed to COVID-19 is at risk of infection, but people with cancer are at increased risk of infection, severe complications and death… -
Health Care Professionals Join Drugwatch.com’s Network of Experts
Drugwatch.com is excited to announce the addition of three respected health care professionals to our network of expert contributors. Along with Drugwatch’s other… -
Drugwatch Writer Joins COVID-19 Press Teleconference Advisory Board
Drugwatch’s senior writer Michelle Llamas has joined the National Center for Health Research’s PCORI COVID-19 Press Teleconference Advisory Board. The…
Calling this number connects you with a Drugwatch representative. We will direct you to one of our trusted legal partners for a free case review.
Drugwatch's trusted legal partners support the organization's mission to keep people safe from dangerous drugs and medical devices. For more information, visit our partners page.
(888) 645-1617